『ASEAN MedTech Insights』のカバーアート

ASEAN MedTech Insights

ASEAN MedTech Insights

著者： Ran Chen
無料で聴く

概要

 Welcome to ASEAN MedTech Insights, the premier podcast dedicated to the thriving medical technology landscape of Southeast Asia. Each episode, we explore the cutting-edge innovations, investment trends, and regulatory developments in one of the world's fastest-growing markets. Join us for exclusive interviews with the founders, executives, and visionaries shaping the future of healthcare in the ASEAN region.Copyright 2026 Ran Chen 生物科学 科学 経済学
エピソード
  • Pure Global | Kuala Lumpur's AI MedTech Gambit: Navigating the New Fast-Track Maze.

    Pure Global | Kuala Lumpur's AI MedTech Gambit: Navigating the New Fast-Track Maze.
    2026/02/12
    In this episode, we dissect the groundbreaking announcement from Malaysia's Medical Device Authority (MDA): a new fast-track approval pathway for AI-powered medical software. This strategic move could slash market entry timelines from years to months, but it comes with a new layer of stringent requirements. We explore how this policy positions Malaysia as a competitive hub for digital health innovation in the ASEAN region. Learn about the specific technical and regulatory hurdles, including new cybersecurity and data privacy mandates, that companies must overcome to leverage this accelerated route. **The Case Study:** A promising MedTech startup developed an AI algorithm for diagnostic imaging. They had market approval in Europe but were stuck in Malaysia's slow, ambiguous regulatory queue for over a year, burning cash and losing their first-mover advantage. The new fast-track pathway is a lifeline, but are their technical documents prepared for the intense scrutiny on cybersecurity and data governance that comes with it? **What You'll Learn:** * What are the precise eligibility criteria for the new Malaysian AI SaMD fast-track? * How does this new pathway change the required content of your technical dossier? * What critical cybersecurity vulnerabilities will regulators be looking for? * Is this new policy a direct challenge to Singapore's regulatory leadership in ASEAN? * How can you leverage your existing international approvals to qualify for this route? * What are the hidden compliance costs associated with the new data governance rules? * Could success in Malaysia create a domino effect for approval in other ASEAN markets? Navigating new and complex regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline global market access. Whether it's compiling a technical dossier for Malaysia's new requirements or developing a multi-market entry strategy, we ensure you are compliant and competitive. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Pure Global: Singapore-Malaysia's New MedTech 'Twin-Market' Shortcut

    Pure Global: Singapore-Malaysia's New MedTech 'Twin-Market' Shortcut
    2026/02/11
    This week, we dive into the groundbreaking news from Singapore and Malaysia. The two nations have launched a joint MedTech registration pilot, creating a unified pathway for market access. This episode dissects what this "twin-market" strategy means for medical device manufacturers and how it could reshape the entire ASEAN regulatory landscape. We explore the practical impact of this collaboration between Singapore's HSA and Malaysia's MDA. For instance, a European diagnostics company was facing a complex, two-year staggered launch plan for Southeast Asia. This new pilot program has suddenly made it possible to access both key markets simultaneously, forcing them to rethink their strategy to capitalize on the opportunity while avoiding the potential compliance pitfalls of a dual submission. Key Takeaways: * What specific device classes (B, C, and D) are eligible for this new fast-track process? * How does this pilot change the strategic importance of Singapore versus Malaysia for a first-market entry? * What are the three critical documentation mistakes to avoid in a "twin-market" submission? * How will this new program affect post-market surveillance and reporting obligations? * Can you truly use a single technical dossier to satisfy both the HSA and MDA? * What are the hidden complexities in this seemingly simplified process? * How does this align with the broader trend of ASEAN regulatory harmonization? Pure Global offers end-to-end regulatory consulting to streamline your global market access. We combine local expertise with advanced AI tools to accelerate registration and ensure compliance. To learn how we can help you leverage new pathways like the Singapore-Malaysia pilot, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Singapore-Malaysia MedTech Corridor: Unpacking the New Regulatory Shortcut with Pure Global.

    Singapore-Malaysia MedTech Corridor: Unpacking the New Regulatory Shortcut with Pure Global.
    2026/02/10
    This week, we dive into the groundbreaking new regulatory pilot program launched between Singapore and Malaysia. This collaboration promises a faster, streamlined approval process for medical devices, creating a powerful new corridor for market access in ASEAN. But what looks like a simple shortcut is filled with critical details that can make or break your entry strategy. Imagine your company, with a device already approved in Singapore, expects a quick entry into Malaysia under the new pilot. However, your application gets bogged down in endless queries. The promised three-month approval stretches into nine, all due to a minor documentation mismatch and a misunderstanding of local representation rules. This episode unpacks the hidden complexities to ensure you seize the opportunity, not the delay. Key Questions Answered in this Episode: - What are the exact eligibility criteria for the Singapore-Malaysia reliance pilot? - How does this new pilot program impact registration fees in each country? - What are the most common documentation errors that could disqualify your device from this fast-track review? - Why is having separate, local authorized representation in both countries still mandatory? - Is this pilot the first step towards a unified ASEAN medical device market? - How can you prepare your technical dossier now to successfully leverage this new corridor? - What specific actions must you take if your device is already on the market in one of the two countries? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise in over 30 markets, including Singapore and Malaysia, with advanced AI tools to streamline global market access. Let us help you navigate the nuances of this new regulatory landscape. Contact us at info@pureglobal.com or visit https://pureglobal.com/ for more information.
    続きを読む 一部表示
    2 分
まだレビューはありません